ClinicalTrials.gg
CompletedNCT03202563Updated Feb 15, 2019

Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)

A Phase 4 interventional study of Gemigliptin 50mg and Dapagliflozin 10mg in Type 2 Diabetes Mellitus, sponsored by LG Chem. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by LG Chem · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. gemigliptin · Diabetes Mellitus, Type 2.

Enrollment
10th of 18
71 · median 130
Started
2017
the only one that year
Phase 4
3 of 18
none open now
Registered
11th of 18
by date
Lead sponsor
7 of 18
LG Chem

Among the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is the only one that started in 2017, is one of 3 in phase 4, and was the 11th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About gemigliptin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The objective of this study is to evaluate the efficacy on glycemic variability and safety of gemigliptin 50 mg orally administered once daily for 12 weeks compared with Dapagliflozin 10mg in patients with type 2 diabetes mellitus who have inadequate glycemic control on metformin alone or diabetes medication naïve patient

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with type 2 diabetes mellitus of 20\~70years of age at the time of Visit 1 (Screening)
  2. Patients with measured in the local lab ranged from 7 to 11%satisfying the following conditions at the time of Visit 1(Screening)

    • Type 2 diabetes mellitus medication naïve patients or patients who had not taken diabetes medication other than metformin within 8 weeks prior to Visit 1(Screening)
    • For patients who have been taking metformin alone within 12 weeks prior to visit 1(Screening) and had taken at least 1000 mg of metformin daily without dose adjustment for 4 weeks prior to Visit 1(Screening)
  3. Patients who have signed an themselves after receiving explanation about the objectives, methods, effects, etc. of the clinical study
  4. Patients who are applicable to one of the three in the following. 1) Surgically infertile patients 2) female patients of ≥45 years of age for whom ≥2 years elapsed since their last menstruation 3) Premenopausal fertile female patients or surgically non-infertile male patients who have agreed to use at least 2 kinds of measures (certainly including one of the barrier methods) to avoid pregnancy until 14 days after the last dose of the product

    • Barrier methods: Condom, Diaphragm, Cervical cap(Pessary), Spermicide
    • Hormonal methods: Pills, Injection(Depot), Skin patch, Hormonal implant(Implanon), Vaginal ring
    • Intrauterine Devices(IUDs): Cooper IUD(Loop), Hormonal IUD(Mirena)
    • Natural methods: Basic body temperature, Ovulation period, Coitus interruptus, Abstinence

Exclusion criteria

Exclusion Criteria:

  1. Patients with type 1 diabetes mellitus*, Diabetic ketoacidosis, Diabetic coma, Diabetic pre-coma
  2. Patients with Gestational diabetes, or secondary diabetes
  3. Patients with (BMI) >40 kg/m2 at the time of Visit 1(Screening)
  4. Patients with a history of the following

    • Patients with Class III, IV congestive heart failure or arrhythmia requiring treatment at the time of Visit 1(Screening)
    • Patients whose TSH level is out of the normal range and who have thyroidal dysfunction requiring drug therapy at the time of Visit 1(Screening) (However, those who have been taking thyroid hormone at a fixed dose since previous 6 weeks prior to Visit 1[Screening] and whose TSH level is within the normal range can participate in the study.)
    • Patients with a (eGFR) less than 60 mL/min /1.73 m2, dnd stage renal disease, dialysis or with renal disease that may result from conditions such as cardiovascular shock, acute myocardial infarction and sepsis, or patients with renal insufficiency at the time of Visit 1(Screening)
    • Patients who are receiving intravenous iodine contrast agents at the time of visit 1(Screening) or planned during the clinical trial period (eg, intravenous urography, venous cholangiography, angiography, computed tomography using contrast media, etc.) ). For patients who have received this test, they can re-evaluate the renal function 48 hours after the test and only participate in clinical trials after they have been found to be normal.
    • Patients with pulmonary embolism, severe pulmonary dysfunction, or who are susceptible to be accompanied by hypoxemia at the time of Visit 1(Screening)
    • Patients on drug therapy due to gastrointestinal disturbance including dehydration, diarrhea, and vomiting at the time of Visit 1(Screening) Patients with severe infection or severe trauma at the time of Visit 1(Screening)
    • Patients with malnutrition status, starvation status, weakness status, pituitary insufficiency or adrenal insufficiency at the time of Visit 1(Screening)
    • Patients with a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma within 12 weeks prior to Visit 1(Screening)
    • Patients with a history of myocardial infarction, unstable angina, and coronary artery bypass graft(CABG) within 12 weeks prior to Visit 1(Screening)
    • Patients who had had a surgical operation within 4 weeks prior to Visit 1(Screening) (excluding minor surgeries without restriction on food and fluid intake) or who are scheduled to have a significant surgery during the study period
    • Patients with a history of alcoholism or drug addiction within 12weaks prior to Visit 1(Screening)
    • Patients with a history of malignant tumors within 5 years prior to Visit 1(Screening). However, patients with basal cell or squamous cell skin cancer, or in situ cervical cancer treated properly can participate in the study.
  5. Patients with the outcomes of the laboratory tests performed at Visit 1(Screening) applicable to the criteria below

    • >2 × (ULN)
    • /ALT >3 × ULN
  6. Patients with a history of reactions to the drugs below

    • Gemigliptin or drugs belonging to dipeptidyl-peptidase4(DPP4) inhibitors
    • Dapagliflozin or drugs belonging to Sodium/glucose co transport-2(SGLT-2) inhibitor
    • Metformin or drugs belonging to biguanides
  7. Patients who were administered the drugs below

    • Patients who had been administered anti-obesity drugs within 4 weeks prior to Visit 1(Screening)
    • Patients who had been administered insulin or GLP-1 analogues within 8 weeks prior to Visit 1(Screening)
    • Patients who had been administered warfarin, dicoumarin, and digoxin within 4 weeks prior to Visit 1(Screening)
    • Patients who are being administered any of the strong inducers (rifampicin[rifampin], dexamethasone, phenytoin, carbamazepine, rifabutin, phenobarbital) at the time of Visit 1(Screening)
    • Patients who had been being administered continuously within 2 weeks prior to Visit 1(Screening) or who are required to take glucocorticoids continuously in the future
  8. Patients with a genetic problems such as Galactose intolerance, Lapp lactose deficiency, Glucose-galactose malabsorption)
  9. Female patients who are pregnant or lactating
  10. Patients who have an experience of participation in another clinical study within 12 weeks prior to Visit1(screening)
  11. Patients who are otherwise considered to be ineligible for this study on investigators' judgment
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Gemigliptin 50mg

    the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total. Drug: Gemigliptin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS)

    Drug: Gemigliptin 50mg · Procedure: Diet/exercise questionnaire · Device: Continuous Glucose Monitoring System(CGMS) · Drug: Metformin

  • Active comparator
    Dapagliflozin 10mg

    the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total. Drug: Dapagliflozin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS)

    Drug: Dapagliflozin 10mg · Procedure: Diet/exercise questionnaire · Device: Continuous Glucose Monitoring System(CGMS) · Drug: Metformin

Interventions

  • For patients who have been randomized to Gemigliptin(Experimental arm), the patients continue to take a gemigliptin 50mg 1 tablet by once daily during study treatment period(Visit 3(day 1)\~Visit 6(day 91))

  • For patients who have been randomized to Dapagliflozin(Active Comparator arm), the patients continue to take a dapagliflozin 10mg 1 tablet by once daily during study treatment period(Visit 3(day 1)\~Visit 6(day 91))

  • ProcedureDiet/exercise questionnaire

    doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regular diet without greater changes in life style as much as possible during the whole study period. the questionnaire regarding diet/exercise will be collected at -day 6, day 1, day29, day85, day 91

  • DeviceContinuous Glucose Monitoring System(CGMS)

    For patients who have been screening completely, the subjects will be attached CGMS(ipro-2) twice from Visit 2(-day 6) to Visit 3(day 1) and Visit 5(day 85) to Visit 6(day 91)

  • For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study

06

What researchers measure

Primary outcomes

  1. Changes from baseline MAGE(Mean amplitude of glycemic excursion) at week 12

    MAGE will be calculated from MBG which has been measured by CGMS(Continuous Glucose Monitoring System) during CGM period(visit 2\~visit 3, visit 5\~visit 6)

    Time frame: baseline (visit 2~visit3) and week 12 (visit 5~visit 6)

Secondary outcomes

  1. Changes from baseline MBG(Mean Blood Glucose) at week 12

    MBG is a mean blood glucose measured by CGMS(Continuous Glucose Monitoring System) during CGM period(visit 2\~visit 3, visit 5\~visit 6)

    Time frame: baseline (visit 2~visit3) and week 12 (visit 5~visit 6)

  2. Changes from baseline SD(Standard Deviation) at week 12

    SD is a standard deviation of MBG measured by CGMS(Continuous Glucose Monitoring System) during CGM period(visit 2\~visit 3, visit 5\~visit 6)

    Time frame: baseline (visit 2~visit3) and week 12 (visit 5~visit 6)

  3. Changes from baseline CV(Coefficient of variance) at week 12

    CV is a coefficient of variance which is MBG divided by SD measured by MBG during CGM period(visit 2\~visit 3, visit 5\~visit 6)

    Time frame: baseline (visit 2~visit3) and week 12 (visit 5~visit 6)

  4. Changes from baseline hsCRP at week 12

    Time frame: baseline (visit 2) and week 12 (visit 5)

  5. Changes from baseline Nitrotyrosine at week 12

    Time frame: baseline (visit 2) and week 12 (visit 5)

Other outcomes

  1. Changes of HbA1c at each visit

    values of parameters at the corresponding visit - values of parameters at visit 2(baseline)

    Time frame: baseline(visit 2), week 5(visit 4), week 13(visit 5)

  2. Changes of Fasting plasma glucose at each visit

    values of parameters at the corresponding visit - values of parameters at visit 2(baseline)

    Time frame: baseline(visit 2), week 5(visit 4), week 13(visit 5)

  3. Changes of Fasting serum insulin at each visit

    values of parameters at the corresponding visit - values of parameters at visit 2(baseline)

    Time frame: baseline(visit 2), week 5(visit 4), week 13(visit 5)

  4. Changes of Glycated albumine at each visit

    values of parameters at the corresponding visit - values of parameters at visit 2(baseline)

    Time frame: baseline(visit 2), week 5(visit 4), week 13(visit 5)

  5. Changes of baseline HOMA-β at week 13

    Time frame: baseline(visit 2), week 13(visit 5)

  6. Changes of baseline HOMA-IR at week 13

    Time frame: baseline(visit 2), week 13(visit 5)

  7. Changes of baseline LDL-C at week 13

    Time frame: baseline(visit 2), week 13(visit 5)

  8. Changes of baseline HDL-C at week 13

    Time frame: baseline(visit 2), week 13(visit 5)

  9. Changes of baseline Total Cholesterol at week 13

    Time frame: baseline(visit 2), week 13(visit 5)

  10. Changes of baselineTriglyceride at week 13

    Time frame: baseline(visit 2), week 13(visit 5)

  11. Changes of baseline BMI at week 13

    Time frame: baseline(visit 2), week 13(visit 5)

  12. Changes of baseline Body weight at week 13

    Time frame: baseline(visit 2), week 13(visit 5)

07

Study locations

1 site
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Jul 2018, 11 months.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 11 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2017
First posted
Jun 28, 2017
StartActual
Aug 9, 2017
Primary completionActual
Jul 13, 2018
CompletionActual
Dec 7, 2018
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03202563
Lead sponsor
LG Chem
Responsible party
Sponsor
First posted
Jun 28, 2017
Start date
Aug 9, 2017
Primary completion
Jul 13, 2018
Completion
Dec 7, 2018
Last update
Feb 15, 2019

Study contacts

Jaehyen Kim
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemigliptin

Start the discussion